COVID Mutants: Vaccine Changes Likely To Need Immunogenicity Studies, Not Big Efficacy Trials
US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. Meanwhile, vaccine developers face challenge of when to change antigens to get the best results, NIH’s Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.
You may also be interested in...
Pandemic Perspectives: How COVID Emergency Use Authorizations Could Reshape US FDA
From re-examining the FDA’s place in the broader US government to how fast and flexible it can be clearing therapies in non-emergency times, the COVID-19 EUA experience is expected to have a long-lasting impact on the agency.
COVID-19 Vaccine Manufacturers Are Not Enthusiastic About Using Defense Production Act
Pfizer and Moderna execs note they have sufficient resources with their partners to meet their vaccine production commitments. J&J, which has a manufacturing arrangement with Sanofi, is ready to ship four million doses of its vaccine upon receiving authorization from FDA.
How US FDA Will Unleash Attack On COVID-19 Variants Once Global Consensus Is Reached
Agency outlines plans to authorize variant COVID-19 vaccines and therapeutics based on swift quality assessments.